Oncternal Therapeutics Inc
NASDAQ:ONCT
Oncternal Therapeutics Inc
Revenue
Oncternal Therapeutics Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Oncternal Therapeutics Inc
NASDAQ:ONCT
|
Revenue
$785k
|
CAGR 3-Years
-39%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
9%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
See Also
What is Oncternal Therapeutics Inc's Revenue?
Revenue
785k
USD
Based on the financial report for Dec 31, 2023, Oncternal Therapeutics Inc's Revenue amounts to 785k USD.
What is Oncternal Therapeutics Inc's Revenue growth rate?
Revenue CAGR 3Y
-39%
Over the last year, the Revenue growth was -47%. The average annual Revenue growth rates for Oncternal Therapeutics Inc have been -39% over the past three years .